Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

Solid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brands Commercial execution and late-stage pipeline investments on schedule, including first approval for ORZEYFULTM (oveporexton) in China, set…